Advancing Pipeline
We are advancing our clinical pipeline of first-in-class monoclonal antibodies with broad-spectrum potential in cancer and viral infections.
|
 |
Clinical Trials
We have multiple company-sponsored clinical trials and an investigator-sponsored trials (IST) program.
|
|
Biomanufacturing Subsidiary
Our subsidiary Avid Bioservices provides a comprehensive range of biomanufacturing services for its clients and manufactures clinical products for our trials.
|
|
Government Contract
Our government contract with the TMTI covers research for up to a five-year period, potentially worth up to $44.5M.
|
|
Growing Body of PS Research
Our novel PS-targeting monoclonal antibodies are validated by a growing body of research.
|
